Literature DB >> 8586509

Hyperbaric oxygenation therapy for cyclophosphamide-induced haemorrhagic cystitis.

H Yazawa1, T Nakada, I Sasagawa, M Miura, Y Kubota.   

Abstract

A 41-year-old female patient undergoing cyclophosphamide therapy for ovarian tumour suffered from haemorrhagic cystitis. Hyperbaric oxygenation (HBO) (100% of oxygen concentration at 2 atmospheric absolute pressures for 60 minutes a day for 30 days) was performed. After treatment the symptom subsided and haematuria disappeared. Cystoscopic findings demonstrated marked improvement. During the course of therapy no side effect was noted. Thus, HBO treatment appeared to have a beneficial effect on cyclophosphamide cystitis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8586509     DOI: 10.1007/bf02550072

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  20 in total

1.  Cyclophosphamide and urinary bladder toxicity.

Authors:  F S PHILIPS; S S STERNBERG; A P CRONIN; P M VIDAL
Journal:  Cancer Res       Date:  1961-12       Impact factor: 12.701

2.  Cyclophosphamide hemorrhagic cystitis requiring urinary diversion.

Authors:  A L Golin; R C Benson
Journal:  J Urol       Date:  1977-07       Impact factor: 7.450

3.  Silver nitrate irrigation to control bladder hemorrhage in children receiving cancer therapy.

Authors:  A P Kumar; E L Wrenn; B Jayalakshmamma; L Conrad; P Quinn; C Cox
Journal:  J Urol       Date:  1976-07       Impact factor: 7.450

4.  Prevention of cyclophosphamide-induced hemorrhagic cystitis.

Authors:  M J Droller; R Saral; G Santos
Journal:  Urology       Date:  1982-09       Impact factor: 2.649

5.  Hyperbaric oxygen therapy for control of intractable cyclophosphamide-induced hemorrhagic cystitis.

Authors:  I A Shameem; T Shimabukuro; S Shirataki; N Yamamoto; T Maekawa; K Naito
Journal:  Eur Urol       Date:  1992       Impact factor: 20.096

6.  Successful treatment of radiation cystitis with hyperbaric oxygen.

Authors:  B G Rijkmans; D J Bakker; N F Dabhoiwala; K H Kurth
Journal:  Eur Urol       Date:  1989       Impact factor: 20.096

7.  Intravesical irrigation with alum for the control of massive bladder hemorrhage.

Authors:  A K Goel; M S Rao; A G Bhagwat; S Vaidyanathan; A K Goswami; T K Sen
Journal:  J Urol       Date:  1985-06       Impact factor: 7.450

8.  Successful hyperbaric oxygenation for radiation cystitis due to excessive irradiation to uterus cancer.

Authors:  T Nakada; T Yamaguchi; I Sasagawa; Y Kubota; H Suzuki; K Izumiya
Journal:  Eur Urol       Date:  1992       Impact factor: 20.096

9.  Open instillation of formalin for cyclophosphamide-induced hemorrhagic cystitis in a child.

Authors:  J M Garat; E Martínez; F Aragona
Journal:  Eur Urol       Date:  1985       Impact factor: 20.096

10.  Treatment of radiation-induced cystitis with hyperbaric oxygen.

Authors:  J P Weiss; F P Boland; H Mori; M Gallagher; H Brereton; D L Preate; E C Neville
Journal:  J Urol       Date:  1985-08       Impact factor: 7.450

View more
  4 in total

1.  Emergent Complications in the Pediatric Hematopoietic Stem Cell Transplant Patient.

Authors:  Ashley Munchel; Allen Chen; Heather Symons
Journal:  Clin Pediatr Emerg Med       Date:  2011-09

2.  Hyperbaric oxygen treatment for refractory haemorrhagic cystitis occurring after chemotherapy and haematopoietic stem cell transplantation: retrospective analysis of 25 patients.

Authors:  Handan Ozturk; Bengusu Mirasoglu; Samil Aktas
Journal:  Diving Hyperb Med       Date:  2022-03-31       Impact factor: 1.228

3.  Hyperbaric oxygen-A new horizon in treating cyclophosphamide-induced hemorrhagic cystitis.

Authors:  S Ajith Kumar; P Prasanth; Kk Tripathi; Pc Ghosh
Journal:  Indian J Urol       Date:  2011-04

4.  Long-term experience of hyperbaric oxygen therapy for refractory radio- or chemotherapy-induced haemorrhagic cystitis.

Authors:  Stephan Degener; Alexander Pohle; Hartmut Strelow; Michael J Mathers; Jürgen Zumbé; Stephan Roth; Alexander S Brandt
Journal:  BMC Urol       Date:  2015-05-08       Impact factor: 2.264

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.